Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B

Published:2022-12 Issue:6 Volume:77 Page:1515-1524
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Ji Dong,Chen Yan,Bi Jingfeng,Shang Qinghua,Liu Huabao,Wang Jia-Bo,Tan Lin,Wang Jing,Chen Yongping,Li Qin,Long Qinghua,Song Laicheng,Jiang Li,Xiao Guangming,Yu Zujiang,Chen Liang,Wang Xiaodong,Chen Da,Li Zhiqin,Dong Zheng,Yang Yongping

Publisher

Elsevier BV

Subject

Hepatology

Reference38 articles.

1. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021

2. Epidemiology and surveillance for hepatocellular carcinoma: new trends;Singal;J Hepatol,2020

3. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine;Fujiwara;J Hepatol,2018

4. Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis;Lok;Nat Rev Gastroenterol Hepatol,2013

5. Therapeutic strategies for hepatitis B virus infection: towards a cure;Fanning;Nat Rev Drug Discov,2019

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The application and functional mechanism of Chinese herbal medicines in the treatment of chronic hepatitis B;Future Virology;2024-09-05

2. Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment;Frontiers in Cellular and Infection Microbiology;2024-08-07

3. Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine;Frontiers in Pharmacology;2024-07-16

4. Chinese guidelines on the management of ascites in cirrhosis;Hepatology International;2024-07-09

5. Chinese consensus on the management of liver cirrhosis;Journal of Digestive Diseases;2024-06